MX2022004331A - Método para prevenir el daño por radiación en las glándulas humanas. - Google Patents
Método para prevenir el daño por radiación en las glándulas humanas.Info
- Publication number
- MX2022004331A MX2022004331A MX2022004331A MX2022004331A MX2022004331A MX 2022004331 A MX2022004331 A MX 2022004331A MX 2022004331 A MX2022004331 A MX 2022004331A MX 2022004331 A MX2022004331 A MX 2022004331A MX 2022004331 A MX2022004331 A MX 2022004331A
- Authority
- MX
- Mexico
- Prior art keywords
- radiation damage
- glands
- preventing human
- radiation
- human glands
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
- A61K38/4893—Botulinum neurotoxin (3.4.24.69)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Emergency Medicine (AREA)
- Optics & Photonics (AREA)
- Endocrinology (AREA)
- Physics & Mathematics (AREA)
- Diabetes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Physical Or Chemical Processes And Apparatus (AREA)
- Radiation-Therapy Devices (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La invención se refiere al campo de la oncología de radiación. El método de acuerdo con la invención comprende el uso de la toxina botulínica y un anticolinérgico para prevenir el daño por radiación en las glándulas y los efectos secundarios provocados por radioligandos. El método de acuerdo con la invención comprende, además, el uso de la toxina botulínica para prevenir el daño por radiación en las glándulas, donde el daño por radiación es provocado por radioligandos. Mediante el uso del método de acuerdo con la invención, la presente invención puede proporcionar protección eficaz de las glándulas para evitar el daño por radiación.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102019215585.5A DE102019215585B4 (de) | 2019-10-10 | 2019-10-10 | Verfahren zur prävention von strahlenschäden in humanen drüsen |
PCT/EP2020/078619 WO2021069740A1 (de) | 2019-10-10 | 2020-10-12 | Verfahren zur prävention von strahlenschäden in humanen drüsen |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022004331A true MX2022004331A (es) | 2022-05-30 |
Family
ID=72944110
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022004331A MX2022004331A (es) | 2019-10-10 | 2020-10-12 | Método para prevenir el daño por radiación en las glándulas humanas. |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP4021483A1 (es) |
JP (1) | JP2022552309A (es) |
KR (1) | KR20220080144A (es) |
CN (1) | CN114746107A (es) |
AU (1) | AU2020361545A1 (es) |
BR (1) | BR112022006877A2 (es) |
CA (1) | CA3153898A1 (es) |
DE (1) | DE102019215585B4 (es) |
IL (1) | IL292125A (es) |
MX (1) | MX2022004331A (es) |
WO (1) | WO2021069740A1 (es) |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6139845A (en) * | 1999-12-07 | 2000-10-31 | Allergan Sales, Inc. | Method for treating cancer with a neurotoxin |
ATE337011T1 (de) * | 2001-02-07 | 2006-09-15 | Beth Israel Hospital | Modifizierte psma-liganden und deren verwendung |
US20080063732A1 (en) * | 2006-07-31 | 2008-03-13 | Hantash Basil M | Method of increasing the efficacy of neurotoxin |
AU2012209274A1 (en) * | 2011-01-24 | 2013-09-12 | Anterios, Inc. | Nanoparticle compositions, formulations thereof, and uses therefor |
WO2016014750A1 (en) * | 2014-07-23 | 2016-01-28 | Landy Toth | Precision chemical ablation and treatment of tissues |
CA2959726A1 (en) * | 2014-09-08 | 2016-03-17 | Molecular Insight Pharmaceuticals, Inc. | Organ protection in psma-targeted radionuclide therapy of prostate cancer |
US11383084B2 (en) * | 2017-04-27 | 2022-07-12 | Palo Alto Investors | Treatment of dermatological conditions via neuromodulation |
-
2019
- 2019-10-10 DE DE102019215585.5A patent/DE102019215585B4/de active Active
-
2020
- 2020-10-12 WO PCT/EP2020/078619 patent/WO2021069740A1/de unknown
- 2020-10-12 KR KR1020227015294A patent/KR20220080144A/ko unknown
- 2020-10-12 EP EP20793290.6A patent/EP4021483A1/de active Pending
- 2020-10-12 AU AU2020361545A patent/AU2020361545A1/en active Pending
- 2020-10-12 JP JP2022521593A patent/JP2022552309A/ja active Pending
- 2020-10-12 CA CA3153898A patent/CA3153898A1/en active Pending
- 2020-10-12 MX MX2022004331A patent/MX2022004331A/es unknown
- 2020-10-12 CN CN202080081331.6A patent/CN114746107A/zh active Pending
- 2020-10-12 BR BR112022006877A patent/BR112022006877A2/pt unknown
- 2020-10-12 IL IL292125A patent/IL292125A/en unknown
Also Published As
Publication number | Publication date |
---|---|
AU2020361545A1 (en) | 2022-05-26 |
CN114746107A (zh) | 2022-07-12 |
DE102019215585B4 (de) | 2022-02-17 |
EP4021483A1 (de) | 2022-07-06 |
WO2021069740A1 (de) | 2021-04-15 |
KR20220080144A (ko) | 2022-06-14 |
CA3153898A1 (en) | 2021-04-15 |
DE102019215585A1 (de) | 2021-04-15 |
BR112022006877A2 (pt) | 2022-07-05 |
IL292125A (en) | 2022-06-01 |
JP2022552309A (ja) | 2022-12-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA199299S (en) | Face shield | |
GB2592699B (en) | Tunnelling shield | |
ES2969032T3 (es) | Estructuras de protección sísmica | |
CA200490S (en) | Face shield | |
GB2583112B (en) | Efficient protection for an IKEv2 device | |
PH12020500166A1 (en) | Method of protecting vascular integrity induced by targeted radiation therapy | |
MX2021009105A (es) | Toxinas apxia, apxiia y apxiiia inactivadas. | |
MX2022004331A (es) | Método para prevenir el daño por radiación en las glándulas humanas. | |
CA198888S (en) | Face shield | |
EP3699388C0 (de) | Beweglich montiertes schutzgitter und verfahren zum behindern eines einbruchversuchs | |
EP4052294A4 (en) | INTEGRATED ASSEMBLIES HAVING SHIELD LINES BETWEEN ACTIVE REGIONS OF NEIGHBORING TRANSISTORS | |
MX2021010152A (es) | Moduladores de la expresion de malat1. | |
GB2603769B (en) | Face shield | |
CA195716S (en) | Face shield | |
CA194439S (en) | Face shield assembly | |
UA42260S (uk) | Щиток захисний для обличчя | |
CA214650S (en) | Face shield | |
GB202011356D0 (en) | Face shield | |
ZAA202000748S (en) | Face shields | |
ZAA202000747S (en) | Face shields | |
ZAA202000746S (en) | Face shields | |
ZAA202000744S (en) | Face shields | |
CA206726S (en) | Protective face mask | |
CA205041S (en) | Protective face mask | |
CA209216S (en) | Protective face mask |